

December 16, 2020

Citi Appointed as Depositary Bank for Nanobiotix SA's ADR Program

Citi, acting through Citibank N.A., has been appointed by Nanobiotix SA ("Nanobiotix"), a French, clinical-stage nanomedicine company, to act as depositary bank for its American Depositary Receipt ("ADR") program.

Nanobiotix's American Depositary Shares ("ADS") trade on the Nasdaq Global Market under the symbol "NBTX". Each ADS represents one ordinary share of the company. Nanobiotix's underlying ordinary shares are listed and trade on Euronext Paris under the symbol "NANO".

Commenting on the appointment, Dirk Jones, Global Head of Issuer Services, at Citi said: "We look forward to supporting Nanobiotix's ADR program and expanding the company's investor outreach through the expertise of our Investor Relations Advisory team and the breadth of our global equity distribution network."

For more information about Citi's Depositary Receipt Services, please visit www.citi.com/dr.

Contacts:

New York

Marisela Lopez

marisela.lopez@citi.com

London

Niccolò Cominacini

niccolo.cominacini@citi.com

Intermediaries & Investors

Group Email

citiadr@citi.com

Visit Bloomberg ADRC <GO>

About Citi

Citi, the leading global bank, has approximately 200 million customer accounts and does business in more than 160 countries and jurisdictions. Citi provides consumers, corporations, governments and institutions with a broad range of financial products and services, including consumer banking and credit, corporate and investment banking, securities brokerage, transaction services, and wealth management.

Additional information may be found at www.citigroup.com | Twitter: [@Citi](https://twitter.com/Citi) | YouTube: www.youtube.com/citi | Blog: <http://blog.citigroup.com> | Facebook: www.facebook.com/citi | LinkedIn: www.linkedin.com/company/citi